bimagrumab tirzepatide Lilly Cuts Mid-Stage Obesity Study of Muscle-Sparing Antibody Weight loss and muscle loss.

Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data

GLP-1 analogues have been shown to have cardiovascular benefits and are generally safe for use in individuals with a history of heart disease

Before enrolling, confirm that services are currently available in your state

Depending on the depth of the panel, these laboratory services cost between $100 and $300 per testing interval

Our clinic is passionate about reducing the burden on emergency rooms, ensuring that patients dont have to wait for hours outside hospitals